Neurocrine Biosciences (NBIX) Q1 Earnings and Revenues Miss EstimatesZacks Investment Research • 05/05/21
Neurocrine Biosciences to Present at the Bank of America 2021 Healthcare ConferencePRNewsWire • 05/04/21
Neurocrine Biosciences Supports Mental Health Month and Tardive Dyskinesia Awareness WeekPRNewsWire • 05/03/21
Neurocrine Biosciences Announces Appointment of Johanna Mercier to Board of DirectorsPRNewsWire • 04/16/21
Neurocrine Biosciences Announces Conference Call and Webcast of First Quarter 2021 Financial ResultsPRNewsWire • 04/14/21
Neurocrine Biosciences to Present Data from its Neurology Portfolio at the American Academy of Neurology's 73rd 2021 Virtual MeetingPRNewsWire • 04/08/21
Strength Seen in Neurocrine (NBIX): Can Its 11.1% Jump Turn into More Strength?Zacks Investment Research • 03/26/21
Neurocrine Biosciences Set to Join S&P MidCap 400; O-I Glass to Join S&P SmallCap 600PRNewsWire • 03/24/21
Neurocrine Biosciences to Present New Data Analyses for Crinecerfont in Adults with Classic Congenital Adrenal Hyperplasia at ENDO 2021PRNewsWire • 03/20/21
Neurocrine Biosciences to Present at the Oppenheimer 31st Annual Healthcare ConferencePRNewsWire • 03/09/21
Neurocrine Biosciences Announces Top-Line Results from Phase II INTERACT Study Evaluating Luvadaxistat (NBI-1065844) for the Treatment of Negative Symptoms and Cognitive Impairment Associated with Schizophrenia (CIAS)PRNewsWire • 03/02/21
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Gorman on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 02/05/21
Neurocrine Biosciences Reports Fourth Quarter and Full-Year 2020 Financial ResultsPRNewsWire • 02/04/21